Making Medicines Easier to Take: XTEMP-R Benefits More than Children with TB
For many children, and plenty of adults, swallowing tablets is hard. Ready-made syrups are often unavailable, poorly palatable, or impractical
Promising New Data on Pediatric Use of Pretomanid in Children with Drug-Resistant Tuberculosis Presented at 2025 Union Conference
Positive results mark an important step forward in efforts to develop effective treatments for children with drug-resistant TB COPENHAGEN, Denmark
Phase 2 Clinical Trial Results Show Potential to Shorten TB Treatment Time
Thuto Pulane, a TB survivor and participant in the NC-009 trial, at a follow-up appointment with Dr. William Brumskine, NC-009
WHO Report Shows TB Gains, But Funding Gaps Threaten Momentum
TB Alliance is gratified to see clear progress against tuberculosis in the latest WHO Global TB Control Report. While TB
Digital First, Faster Access: How TB Alliance Is Using Tech to Speed BPaL/M to People Who Need It
For decades, breakthrough TB science has too often moved slowly from approval to those in need. In the roll out
TB Alliance Launches Upskill TB Platform in Collaboration with Indonesia’s Ministry of Health and RPRI Foundation
Digital Training Platform, Upskill TB, Strengthens Capacity to Deliver New DR-TB Treatments JAKARTA (October 9, 2025)—TB Alliance, in collaboration with
DR-TB Regimen Will Save 190,000+ Additional Lives and $1.29B by 2035
The six-month, all-oral BPaL/M regimens for the treatment of drug-resistant TB (DR-TB) are already changing the trajectory of DR-TB care
New Report Finds Investing in Global Health R&D Delivers Returns at Home and Abroad
The investment case for global health R&D is increasingly evidence-based. Impact Global Health’s new Ripple Effect analysis tracks what happens
New Study Finds Investing in Shorter, More Effective TB Treatment Pays Off
A new analysis, published in IJTLD Open, from South Africa and the Philippines further confirms that six-month, all-oral BPaL/M regimens
TB Alliance Welcomes WHO Prequalification of Lupin’s Pretomanid Product
NEW YORK (September 12, 2025)—Lupin Limited, a leading pharmaceutical company headquartered in India, has been granted prequalification by the World